摘要
目的:观察安罗替尼联合多西他赛治疗晚期非小细胞肺癌的临床疗效及安全性。方法:选取浙江金华广福肿瘤医院2018年3月至2019年6月收治的晚期非小细胞肺癌患者118例为研究对象,采用随机数字表法将患者分为研究组和对照组,各59例。对照组患者予以多西他赛治疗,研究组患者予以安罗替尼联合多西他赛治疗。治疗2个疗程后,比较两组临床治疗效果、患者无进展生存期和1年生存率及治疗期间药物不良反应。结果:两组患者客观缓解率(22.03%比32.20%)差异无统计学意义(χ^(2)=1.544,P=0.214);研究组患者疾病控制率(88.14%)显著高于对照组(69.49%)(χ^(2)=6.141,P=0.013);研究组无进展生存期6.92个月(95%CI:3.83~9.54个月),显著长于对照组的3.84个月(95%CI:2.08~6.17个月)(χ^(2)=5.934,P=0.019);随访,研究组患者1年期生存率为52.47%(31/59),显著高于对照组的32.20%(19/59)(χ^(2)=4.998,P=0.025);研究组患者治疗期间白细胞减少(20.34%)、红细胞减少(13.56%)、胃肠道不良反应(28.81%)和肝肾功能异常发生率(5.08%)均高于对照组(16.95%、10.17%、23.73%和3.39%),但差异均无统计学意义(χ^(2)=0.211~0.835,P=0.361~0.646)。结论:安罗替尼联合多西他赛可有效抑制非小细胞肺癌的进展,延长无进展生存期,提高1年生存率,且不增加药物不良反应。
Objective To investigate the clinical efficacy and safety of anlotinib combined with docetaxel for the treatment of advanced non-small cell lung cancer.Methods A total of 118 patients with advanced non-small cell lung cancer who received treatment in Jinhua Guangfu Cancer Hospital from March 2018 to June 2019 were included in this study.They were randomly assigned to receive treatment with either anlotinib combined with docetaxel(study group,n=59)or docetaxel alone(control group,n=59)for two treatment courses.Clinical efficacy,progression-free survival,1-year survival rate,and adverse drug reactions were compared between the study and control groups.Results There was no significant difference in the objective remission rate between the two groups(22.03%vs.32.20%,χ^(2)=1.544,P=0.214).The disease control rate in the study group was significantly higher than that in the control group(88.14%vs.69.49%,χ^(2)=6.141,P=0.013).Progression-free survival in the study group was significantly longer than that in the control group[6.92 months(95%CI:3.83-9.54 months)vs.3.84 months(95%CI:2.08-6.17 months),χ^(2)=5.934,P=0.019).The 1-year survival rate in the study group was significantly higher than that in the control group[52.47%(31/59)vs.32.20%(19/59),χ^(2)=4.998,P=0.025].During the treatment,the proportion of patients having leucopenia,erythropenia,gastrointestinal adverse reactions and abnormal liver and kidney function in the study group was 20.34%,13.56%,28.81%and 5.08%,respectively,which was significantly higher than 16.95%,10.17%,23.73%and 3.39%,respectively in the control group(χ^(2)=0.211-0.835,P=0.361-0.646).Conclusion Arotinib combined with docetaxel can effectively inhibit the progression of non-small cell lung cancer,prolong the progression-free survival,increase the 1-year survival rate,and does not increase adverse drug reactions.
作者
陈华春
柏帆
余旭舟
李雯雯
Chen Huachun;Bai Fan;Yu Xuzhou;Li Wenwen(Department of Respiratory Medicine,Jinhua Guangfu Cancer Hospital,Jinhua 321000,Zhejiang Province,China)
出处
《中国基层医药》
CAS
2021年第4期584-587,共4页
Chinese Journal of Primary Medicine and Pharmacy
关键词
癌
非小细胞肺
抗肿瘤联合化疗方案
安罗替尼
多西他赛
Carcinoma,non-small-cell lung
Antineoplastic combined chemotherapy protocols
Anlotinib
Docetaxel
